Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

Condition:   Acute Myeloid Leukemia Interventions:   Drug: Dose Escalation -tagraxofusp-erzs;   Drug: Dose Expansion at RP2D -tagraxofusp-erzs Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   StemlineTherapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials